➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Johnson and Johnson
McKinsey
Moodys
Harvard Business School

Last Updated: October 24, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for piperacillin sodium; tazobactam sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00389987 ↗ Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037) Completed Merck Sharp & Dohme Corp. Phase 3 2001-09-01 This study is designed to compare the efficacy of ertapenem and piperacillin/tazobactam with respect to the clinical response in baseline microbiologically evaluable patients; and to evaluate the tolerability and safety of ertapenem compared to piperacillin/tazobactam.
NCT00873327 ↗ Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates Completed Phillip Brian Smith Phase 1 2009-10-01 This is a phase I open label multi-dose study to investigate the pharmacokinetics and safety of piperacillin-tazobactam in infants < 61 days of age with suspected sepsis. There will be four cohorts of 8 infants each: 1. < 32 weeks gestational age (GA) and < 14 days postnatal age (PNA) 2. < 32 weeks gestational age and >=14 days postnatal age 3. >=32 weeks gestational age and < 14 days postnatal age 4. >=32 weeks gestational age and >=14 days postnatal age. The study requires administration of 6 doses of study drug along with other antimicrobials per standard of care followed by 1 week of safety monitoring. Four 200 ┬ÁL pK samples will be obtained at steady state. The risks are reasonable vs. the benefits and have been minimized appropriately. There may be benefit to the subjects (administration of broad spectrum empirical antimicrobial therapy), and information from the study may benefit a large number of other infants in whom the drug is currently being administered despite the lack of PK data in this population.
NCT01370616 ↗ Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061) Completed Merck Sharp & Dohme Corp. Phase 3 2011-09-01 This study compared ertapenem sodium to piperacillin/tazobactam sodium for the treatment of moderate to severe diabetic foot infections. The primary hypothesis was that treatment with ertapenem sodium is non-inferior to treatment with piperacillin/tazobactam sodium, in achieving clinical improvement or cure.
NCT02466438 ↗ Safety and Pharmacokinetics of Piperacillin-tazobactam Extended Infusion in Infants and Children (PIP-TAZO) Recruiting St. Justine's Hospital Phase 1 2016-01-01 Severe infection is one of the main causes of disease in hospitalized children and can be deadly. With the lack of novel antibiotics approved in children and the emergence of drug resistant bacteria, there is a critical need to optimize dosing of existing antibiotics. Piperacillin-tazobactam is an antibiotic frequently used for treatment of severe infection in children in Canadian hospitals. To optimize this antibiotic's efficacy despite the rise of antibiotic resistance, alternative dosing strategy is commonly used in adults, which consists of prolonging the time during which the drug is infused (4 hours instead of 30 min). Children clear piperacillin-tazobactam from their bodies at a slower rate than adults, consequently extended-infusion strategy cannot be directly extrapolated from adult to children. We believe that younger children need piperacillin-tazobactam infusions that are shorter compared to adults to achieve appropriate concentrations.
NCT04983901 ↗ Imipenem, Cilastatin Sodium, and Relebactam Monohydrate for the Treatment of Cancer Patients With Febrile Neutropenia Not yet recruiting M.D. Anderson Cancer Center Phase 2 2021-08-10 This phase II trial studies the effect of imipenem-relebactam in treating patients with cancer who have a fever due to low white blood cell counts (febrile neutropenia). In this study, imipenem-relebactam will be compared to the standard-of-care treatment (cefepime, meropenem, or piperacillin/tazobactam) for the treatment of febrile neutropenia. Imipenem-relebactam is used to treat infections. Giving imipenem-relebactam may help to control febrile neutropenia in patients with cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for piperacillin sodium; tazobactam sodium

Condition Name

Condition Name for piperacillin sodium; tazobactam sodium
Intervention Trials
Complicated Intra-Abdominal Infections 1
Sepsis 1
Malignant Solid Neoplasm 1
Infection; Diabetic Foot 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for piperacillin sodium; tazobactam sodium
Intervention Trials
Infection 2
Communicable Diseases 2
Intraabdominal Infections 1
Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for piperacillin sodium; tazobactam sodium

Trials by Country

Trials by Country for piperacillin sodium; tazobactam sodium
Location Trials
United States 5
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for piperacillin sodium; tazobactam sodium
Location Trials
Texas 1
North Carolina 1
Missouri 1
Kansas 1
Indiana 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for piperacillin sodium; tazobactam sodium

Clinical Trial Phase

Clinical Trial Phase for piperacillin sodium; tazobactam sodium
Clinical Trial Phase Trials
Phase 3 2
Phase 2 1
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for piperacillin sodium; tazobactam sodium
Clinical Trial Phase Trials
Completed 3
Recruiting 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for piperacillin sodium; tazobactam sodium

Sponsor Name

Sponsor Name for piperacillin sodium; tazobactam sodium
Sponsor Trials
Merck Sharp & Dohme Corp. 2
St. Justine's Hospital 1
Phillip Brian Smith 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for piperacillin sodium; tazobactam sodium
Sponsor Trials
Other 3
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
McKinsey
Boehringer Ingelheim
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.